RE:RE:RE:RE:RE:RE:RE:RE:RE:Candel Therapeutics not addressing metastatic PDACSo if Candel Therapeutics OV works ... then it goes that so does ONCY's pelareorep in combinaton with an immune checkpoint inhibitor - thus making ONCY an even greater acquisition candidate for Big Pharma - particularly since pelareorep can be granted an Accelerated Approval and on the market in short order.
Let me remind you that ONCY's Phase 2 Goblet study showed that pelareorep works in metastatic pancreatic cancer (mPDAC) with a mPFS of 7.2 months, a ORR of 62% and mOS of 10.6 months and not just for borderline resectable PDAC - as outlined in the below attached link and summarized below. Summary of Data and Findings from the PDAC Arm of the Phase 1/2 GOBLET Study:
Tumor Responses: Consistent with the abstract, data from the study outlined patient responses, including:
- Objective Response Rate (ORR) of 62% (54% confirmed by two or more scans)
- A Disease Control Rate (DCR) of 85%
Survival data: Evaluated based on 4 parameters including:
- Median duration of response was 5.7 months
- Median progression-free survival (PFS) was 7.2 months
- Interim 12-month survival rate was 46%
- Interim median overall survival (OS) was 10.6 months
T-Cell Populations: Analysis of changes of T-cell clones and tumor-infiltrating lymphocytes (TILs) showed:
- Mean baseline TIL cell levels of 22%
- Expansion of pre-existing and new T cell clones, including the expansion of TIL-specific clones
- A correlation between the expansion in the blood of TIL-specific clones and tumor response
Safety: The treatment combination has been well tolerated with no safety concerns
https://www.prnewswire.com/news-releases/oncolytics-presents-positive-updated-pancreatic-cancer-data-from-goblet-phase-12-study-at-esmo-301964264.html